Castle Biosciences
Castle Biosciences Q3 Revenues up 39 Percent
The company saw growth across its melanoma, squamous cell carcinoma, Barrett's esophagus, and pharmacogenomics tests.
360Dx Top 30 Falls 3 Percent in October
Out of the 30 companies tracked by 360Dx, 22 saw their share prices decline, seven saw their stock prices increase, and one company’s shares remained essentially flat.
360Dx Top 30 Ticks up 2 Percent in August
Of the 30 companies in the index, 17 saw their share price increase, 12 saw their stock price decline, and one remained flat month over month.
Castle Biosciences Q2 Revenues Jump 74 Percent
The firm saw particularly high volume growth for its newer tests, including assays for Barrett's esophagus and IDgenetix, its recently acquired PGx assay.
Palmetto Declines to Cover Molecular Risk Stratification Tests for Cutaneous Squamous Cell Carcinoma
The three other Medicare administrative contractors that participate in the MolDx program aligned their coverage with Palmetto's.